Results 251 to 260 of about 236,050 (356)

The Contribution of Cytologic Imprints of Stereotactically Guided Core Needle Biopsies of the Breast in the Management of Patients with Mammographic Abnormalities

, 2001
Rennae S. Green, Seema Mathew
openalex   +1 more source

Core needle biopsy in male breast lesions [PDF]

, 2003
Pieter J. Westenend
openalex   +1 more source

cGAS Inhibits ALDH2 to Suppress Lipid Droplet Function and Regulate MASLD Progression

Advanced Science, EarlyView.
cGAS is a cytosolic DNA sensor known for innate immune defense. cGAS binds and suppresses ALDH2 are showed, limiting acetyl‐CoA production. cGAS loss activates ALDH2, promoting histone acetylation, lipogenesis, and lipid droplets accumulation. cGas‐/‐ mice on a high‐fat diet show signs of worsened MASLD.
Ying Wang, Yu Deng, Jianfeng Chen, Quentin Hahn, David S. Umbaugh, Zhigang Zhang, Yanqiong Zhang, Sarah E. Rowe, Lupeng Li, Laura E. Herring, Brian P. Conlon, Edward A. Miao, Blossom Damania, Anna Mae Diehl, Pengda Liu   +14 more
wiley   +1 more source

Optimizing Precision: A Trajectory Tract Reference Approach to Minimize Complications in CT-Guided Transthoracic Core Biopsy. [PDF]

Diagnostics (Basel)
Tsai SC, Wu TC, Lin FC.
europepmc   +1 more source

The Role of Core Biopsy versus Vacuum-Assisted Breast Biopsy In Primary Breast Angiosarcoma. [PDF]

Case Rep Radiol, 2021
Abate A, Querques G, Giovanazzi R, Di Bella C, Besostri V, Gisabella M, Maino C, Ippolito D, Corso R.   +8 more
europepmc   +1 more source

Adenosis Tumor of the Breast Containing Ductal Carcinoma In Situ, a Pitfall in Core Needle Biopsy

, 2001
Pieter J. Westenend, Sik J. Liem
openalex   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Tumour Seeding Following Core Biopsy of a Mucoepidermoid Carcinoma of the Parotid: Radiological Evidence and a Surgical Approach to En-Bloc Dissection of the Mass and Tract. [PDF]

Cureus, 2022
Ringrose T, Olley BM, Ozbek L, Zhu Y, Hughes J.   +4 more
europepmc   +1 more source

Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma

Advanced Science, EarlyView.
Lung squamous cell cancer (LUSC) is deadly due to lack of good treatments. Here, multiomics techniques are applied to LUSC tumors and find thousands of cancer‐specific enhancers controlling key genes. Interestingly, the gene PTPRZ1 is identified as a critical oncogene driven by the LUSC‐acquired enhancers. PTPRZ1 is activated by MDK, fueling cancer via
Yong‐Qiang Ning, Jie Wang, Yihui Zhang, Hongrui Li, Zenan Jiang, Xinyu Su, Xiao Yang, Xiaoxuan Wu, Bing Wei, Jianmin Ying, Jian Yan, Wenbin Li   +11 more
wiley   +1 more source